Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 2.02, 7.01, 9.01 · 8-K

Hyperfine, Inc.

HYPRNASDAQEQUITYCurrent

Results of Operations and Financial Condition · Regulation FD Disclosure

Item 2.02 Results of Operations and Financial Condition. On January 12, 2026, Hyperfine, Inc. (the “Company”) issued a press release and updated its corporate presentation (the “Investor Presentation”), as described further below, each of which included information with respect to certain preliminary unaudited financial results of the Company.…

Filed Jan 12, 2026Accepted Jan 12, 2026, 8:28 AM ESTCIK 1833769Accession 0001193125-26-009859
Share

Company context

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system - the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit hyperfine.io.

Current securities

Historical securities (1)

Recent company filings

  1. S-3 filingNov 9, 2026
  2. 10-Q filingNov 9, 2026
  3. Results of Operations and Financial ConditionNov 9, 2026
  4. Results of Operations and Financial Condition · Regulation FD DisclosureOct 8, 2026
  5. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingSep 18, 2026

Registered securities in this filing

Hyperfine, Inc. · 8-K · Filed 2026-01-12

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Class A common stock, $0.0001 par value per share

Symbol
HYPR
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: duration_2026-01-12_to_2026-01-12

Dimensions: Not supplied

Accession 000119312526009859 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On January 12, 2026, Hyperfine, Inc. (the “Company”) issued a press release and updated its corporate presentation (the “Investor Presentation”), as described further below, each of which included information with respect to certain preliminary unaudited financial results of the Company. For the quarter ended December 31, 2025, the Company had estimated total revenue of approximately $5.3 million, for the fiscal year ended December 31, 2025, the Company had estimated total revenue of approximately $13.5 million, and the Company had estimated cash and cash equivalents of approximately $35.1 million as of December 31, 2025. The estimated total revenue for the quarter and year ended December 31, 2025 and the estimated cash and cash equivalents as of December 31, 2025 are preliminary and may change, and are based on information available to management as of the date of this Current Report on Form 8-K (the “Report”) and are subject to completion by management of the financial statements as of and for the year ended December 31, 2025. There can be no assurance that the Company’s total revenue for the quarter or year ended December 31, 2025 or the cash and cash equivalents as of December 31, 2025 will not differ from these estimates and any such changes could be material. The preliminary financial data included in this Report has been prepared by and is the responsibility of the Company’s management. The Company’s independent registered public accounting firm has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, the Company’s independent registered public accounting firm does not express an opinion or any other form of assurance with respect thereto. Complete results will be included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. The information in this Item 2.02 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosures. On January 12, 2026, the Company issued a press release entitled “Hyperfine Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results”, a copy of which is attached and furnished hereto as Exhibit 99.1. In addition, on January 12, 2026, the Company updated its Investor Presentation, which management intends to use from time to time in general corporate communications, investor communications and conferences. A copy of the Investor Presentation is attached and furnished hereto as Exhibit 99.2 and is also available on the “Investor Relations” portion of the Company’s website. The Investor Presentation is current as of January 12, 2026, and the Company disclaims any obligation to update the Investor Presentation after such date. The information in this Item 7.01 and Exhibits 99.1 and 99.2 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (2)
EX-99.1 (by filename) d949104dex991.htm

Exhibit 99.1 Hyperfine Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results Hyperfine Delivers Quarterly Record Revenue of Approximately $5.3 Million in Q4 2025, Representing Transformative Growth of 54% Compared to Prior Quarter; Exiting 2025 with Approximately $35 Million of Cash and Cash Equivalents. Guilford, CONN. - January 12, 2026 - Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain - the Swoop® system - today announced preliminary, unaudited revenue, net cash burn, and cash and cash equivalents for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Preliminary, Unaudited Financial Results Preliminary, unaudited revenue for the fourth quarter 2025 is expected to be approximately $5.3 million, representing growth of 127% compared to the fourth quarter of 2024 and 54% sequentially compared to the third quarter of 2025. Preliminary, unaudited net cash burn for the fourth quarter of 2025 excluding financings is expected to be approximately $5.7 million1, down 30% compared to the f…

Open exhibit ↗
EX-99.2 (by filename) d949104dex992.htm

Exhibit 99.2 AI-POWERED, PORTABLE BRAIN MRI The Swoop® Portable MR Imaging System is Driving the Future of Brain Health Corporate Investor Deck - January 2026 The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo is a trademark of Hyperfine, Inc. PROPERTY OF HYPERFINE. ©2026. All rights reserved. Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s goals and commercial plans, including …

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.